Drug intelligence / Profile preview

compound amino acid (19) + alanyl-glutamine

Development stage
Unknown
Lead developer
Academy of Military Medical Sciences
Modality
Peptides, Small Molecules
Administration
Intravenous
01

Overview

Compound amino acid (19) + alanyl-glutamine is a specialized parenteral nutrition formulation developed by the Institute of Radiation and Radiation Medicine at the Academy of Military Medical Sciences in China. It consists of a balanced mixture of 19 essential and non-essential amino acids (specifically the 19AA-I formulation) supplemented with the stable dipeptide alanyl-glutamine. This combination is designed to provide a high-quality nitrogen source for patients in severe catabolic states, such as those following major trauma, surgery, or burns. Alanyl-glutamine serves as a stable precursor to L-glutamine, an amino acid that becomes conditionally essential during critical illness to support the immune system, maintain intestinal mucosal integrity, and preserve muscle mass. The product is administered intravenously to maintain nitrogen balance and promote recovery in patients who cannot receive adequate enteral nutrition.

Brand names
Jun'an
Other names
Compound Amino Acid (19) and Alanyl-Glutamine Injection19AA-I + Alanyl-Glutamine复方氨基酸(19)丙氨酰谷氨酰胺注射液
02

Targets

RibosomeSERPINA1 (Alpha-1-antitrypsin)

Beyond the preview

Go deeper on compound amino acid (19) + alanyl-glutamine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on compound amino acid (19) + alanyl-glutamine.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call